Nelson memo

The Nelson Memo: Igniting a Global Open Data Revolution

The landscape of scientific research is undergoing a seismic shift, driven by an urgent demand for transparency, reproducibility, and equitable access. At the epicenter of this transformation in the United States is the Nelson Memo, a policy directive rapidly accelerating the future of open science. With the National Institutes of Health (NIH)'s recent announcement (NOT-OD-25-101)…...
Read More

Top Stories

MAPS 2025

MAPS 2025 Decoded: The Medical Affairs Playbook

At the MAPS Americas 2025 conference in New Orleans, one of...
DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for

Digital and AI were hot topics underpinning many of the...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
How Can Preprints Drive Trust In Science?

How Can Preprints Drive Trust in Science?

By tagging preprints with various indicators, badges may represent quality, rigor, and scope. In doing...
equity diversity and inclusion

How to Incorporate and Drive Equity, Diversity, and Inclusion in Medical Communications and Publications

A roadmap on how to drive advocacy for EDI in medical communications and publications and...
reimagining scientific communications

Scientific Communication Strategies for Digital Transformation

Read how digital transformation strategies can help to rethink workflows for future readiness and scale-up...
Medical Affairs - 2025

Vision 2025: Decoding the Medical Affairs Landscape

Medical Affairs is a critical strategic pillars of pharma. Read how Medical Affairs will evolve...
Using digital enhancements to maximize engagement

Using Digital Enhancements to Maximize Engagement: How Are Pharma and Publishers Embracing Digital?

Best practices to implement digital enhancements and measure effectiveness...
Pros and cons of preprints for pharma

Preprints and Pharma: What Works and What Doesn’t

Pharma is cautious of preprints. But should this change? Let’s weigh the pros & cons...

Learn more ABOUT our company.